Published in Medical Letter on the CDC and FDA, October 31st, 2004
As participants continue to become ever more conscious of its high-tech appeal, their initial hesitation to diverge from an established practice is likely to decrease.
New analysis from Frost & Sullivan, U.S. Molecular Diagnostics Markets, reveals that revenue in this market totaled $1.22 billion in 2004 and is projected to reach $3.68 billion in 2010.
"Though physicians are rather wary of adopting new techniques, the growing number of clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA